| PBSCs | BM | Cord Blood | T-cell–Depleted BM/PBSCs | Haploidentical T-cell–Depleted BM/PBSCs | |
|---|---|---|---|---|---|
| T-cell content | High | Moderate | Low | Very low | Very low |
| CD34+ content | Moderate–high | Moderate | Low (but higher potency) | Moderate–high | Moderate–high |
| Time to neutrophil recovery | Rapid: median, 16 d (11–29 d) [60] | Moderate: median, 21 d (12–35 d) [60] | Slower: median, 23 d (11–133 d) [33] | Rapid: median, 16 d (9–40 d) [61] | Rapid: median, 13 d (10–20 d) [62] |
| Early post-HSCT risk of infections, EBV-LPD | Low–moderate | Moderate | High | Very high | Very high |
| Risk of graft rejection | Low | Low–moderate | Moderate–high | Moderate–high | Moderate–high |
| Time to immune reconstitutiona | Rapid (6–12 mo) | Moderate (6–18 mo) | Slow (6–24 mo) | Slow (6–24 mo) | Slow (9–24 mo)b |
| Risk of acute GVHD | Moderate | Moderate | Moderate | Low | Low |
| Risk of chronic GVHD | High | Moderate | Low | Low | Low |
BM = bone marrow; EBV-LPD = Epstein-Barr virus–associated lymphoproliferative disorder; GVHD = graft-versus-host disease; HSCT = hematopoietic stem cell transplant; PBSCs = peripheral blood stem cells.
aAssuming no development of GVHD. If patients develop GVHD, immune reconstitution is delayed until resolution of the GVHD and discontinuation of immune suppression.
bIf a haploidentical donor is used, longer times to immune reconstitution may occur.
From: Pediatric Allogeneic Hematopoietic Stem Cell Transplant (PDQ®)
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.